NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

“…Current recommendation for BTK-i treatment is until progression or unacceptable toxicity, therefore the total cost for long-term therapy can be very high. Three studies [61][62][63] conducted in the United Kingdom and United States have tried to analyze cost-effectiveness of this therapy. Very high costs were associated with continuous and indefinite ibrutinib treatment, and drug acquisition costs seem to be a key driver in cost-effectiveness for ibrutinib across studies.…”